CJC-1295 vs Ipamorelin
CJC-1295 vs ipamorelin: a GHRH analogue versus a ghrelin mimetic. How they differ, why they are paired, risks, and what users report.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
They are not alternatives so much as two halves of one signal. CJC-1295 mimics GHRH (the "release" signal); ipamorelin mimics ghrelin at the GH-secretagogue receptor. That is why they are usually sold and used together. Neither is an approved medicine. In this archive almost every report names both, so effects cannot be split between them — see the CJC-1295 + ipamorelin page. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- What is the difference between CJC-1295 and ipamorelin?
- CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin mimetic. They raise growth hormone through different receptors.
- Why are they combined?
- Small studies of GHRH plus ghrelin-type agonists show a larger GH release together than either alone. That is the rationale users cite.
- Does Peptide Confessions give dosing?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
- CJC-1295 vs ipamorelin — what is the difference?
- CJC-1295 is a GHRH analogue; ipamorelin is a GHRP-class secretagogue. People often discuss them together, but they are not the same peptide.
- Where are the reports?
- See the CJC-1295 hub, the Ipamorelin hub, and the CJC-1295 + Ipamorelin stack topic.
- Does this page give a stack protocol?
- No. We never publish dosing or stack instructions.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.